United Therapeutics Given New $93.00 Price Target at RBC Capital (UTHR)
RBC Capital upped their target price on shares of United Therapeutics (NASDAQ:UTHR) from $90.00 to $93.00 in a research note issued on Thursday. RBC Capital’s target price points to a potential downside of 0.31% from the stock’s previous close.
In other United Therapeutics news, COO Roger Jeffs sold 50,000 shares of the stock on the open market in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $96.25, for a total transaction of $4,812,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
United Therapeutics (NASDAQ:UTHR) opened at 93.29 on Thursday. United Therapeutics has a one year low of $70.34 and a one year high of $116.65. The stock has a 50-day moving average of $91.14 and a 200-day moving average of $97.54. The company has a market cap of $4.494 billion and a price-to-earnings ratio of 21.34.
United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, July 29th. The company reported $2.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 15.0% on a year-over-year basis. Analysts expect that United Therapeutics will post $7.96 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Credit Suisse raised their price target on shares of United Therapeutics from $75.00 to $100.00 in a research note on Wednesday. They now have a “neutral” rating on the stock. Finally, analysts at Credit Suisse upgraded shares of United Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, June 16th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $102.33.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.